Subject(s)
Central Nervous System Cysts/diagnostic imaging , Hemangioma, Cavernous, Central Nervous System/diagnostic imaging , Magnetic Resonance Imaging , Thyroid Dysgenesis/diagnostic imaging , Thyroid Dysgenesis/pathology , Thyroid Gland/pathology , Cabergoline , Central Nervous System Cysts/drug therapy , Dopamine Agonists/therapeutic use , Ergolines/therapeutic use , Female , Hemangioma, Cavernous, Central Nervous System/drug therapy , Humans , Prolactin/blood , Thyroid Gland/abnormalities , Thyroid Gland/diagnostic imaging , Treatment Outcome , Young AdultABSTRACT
Dyslipidemia is a primary, major risk factor for coronary artery disease CAD. The prevalence of dyslipidemia had decreased over the past 30 years, which may in part be explained by the steady increase in the use of lipid-lowering drug therapy, especially statins. Cardiovascular risk has been shown to be greater in liver disease (20% in the liver cirrhosis vs. 12% in the general population), where statins can play an important role as a primary and secondary prevention for CAD. Given patients with chronic liver disease, especially liver cirrhosis are at risk of decreased hepatic clearance, there is concern that this patient population may be at higher risk for complications from statin therapy. Several retrospective studies showed that statin use in chronic liver disease and cirrhosis is safe, and even it was associated with lower mortality and lower rate of hepatic decompensation. This review discusses the safety and the different mechanisms where statins can decrease the rate of complications in liver cirrhosis, including portal hypertension, sepsis and the incidence of hepatocellular carcinoma.
Subject(s)
Coronary Artery Disease , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Liver Cirrhosis , Animals , Coronary Artery Disease/metabolism , Coronary Artery Disease/mortality , Coronary Artery Disease/prevention & control , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Liver Cirrhosis/drug therapy , Liver Cirrhosis/metabolism , Liver Cirrhosis/mortalityABSTRACT
La estrechez y oclusión progresiva de la porción distal de las arterias carótida interna, cerebral medial proximal o cerebral anterior, y de sus ramas mayores puede resultar en la hipertrofiade las arterias lenticuloestriadas. Consecuentemente, una fina red de colaterales se forma desde el segmento ocluido en la vecindad del área estenótica. Se describe un caso hemorrágico de moyamoyaque afecta el tálamo. Ésta es una atípicaforma de presentación, puesto que las hemorragias en pacientes no japoneses no exceden del 5 por ciento. Se trata de una mujer pakistaní de 47 años, hipertensa, que presentó, de manera súbita, cefalea, mareos y hemiparesia izquierda, asociados a un nivel deconciencia fluctuante....
Subject(s)
Humans , Female , Middle Aged , Moyamoya Disease/complications , Cerebral Hemorrhage/etiology , Moyamoya Disease/therapyABSTRACT
This report includes five cases afflicted by chronic mercury poisoning which was observed in Iraq in 1972. All five cases showed the symptomatology of a severe cerebral damage combined with peripheral nerve lesion. The clinical picture reveals an apallic syndrome or a prestage ensuring in the full-blown picture. The combination of CNS lesions with polyneuropathy is typical of mercury poisoning with failure of all brain functions and the appearance of brain stem automatism, combined with severe muscular atrophy. When such conditions are established the remission seems to be impossible. The historical as well as the clinical and morphological facts of the Minamata disease is reviewed. The different stages of chronic mercury poisoning in Iraq are described.
